Biodexa Pharmaceuticals Plc
BDRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001643918
No open-market purchases or sales by Biodexa Pharmaceuticals Plc insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $48.1K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Biodexa Pharmaceuticals Plc changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 5 | 7 | +2 |
| Shares | 12.1K | 63.7K | +51.6K (+426.4%) |
| Value | $58.9K | $169.2K | +$110.3K (+187.1%) |
New holders (4)
Institutions that held Biodexa Pharmaceuticals Plc at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Boothbay Fund Management, LLC | 44,593 | $119.5K | 0.00% |
| Renaissance Technologies LLC | 11,700 | $31.0K | 0.00% |
| Bank of America Corp | 5,236 | $14.0K | 0.00% |
| GAMMA Investing LLC | 1,036 | $1.67K | 0.00% |
Sold out (2)
Institutions that held Biodexa Pharmaceuticals Plc at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 11,737 | $57.2K |
| Tower Research Capital LLC (TRC) | 51 | $254 |